OBJECTIVE: Arthrogenic alphaviruses such as Ross River virus (RRV) and chikungunya virus (CHIKV) circulate worldwide. This virus class causes debilitating illnesses that are characterized by arthritis, arthralgia, and myalgia. In previous studies, we identified macrophage migration inhibitory factor (MIF) as a critical inflammatory factor in the pathogenesis of alphaviral diseases. The present study was undertaken to characterize the role of CD74, a cell surface receptor of MIF, in both RRV- and CHIKV-induced alphavirus arthritides. METHODS: Mouse models of RRV and CHIKV infection were used to investigate the immunopathogenesis of arthritic alphavirus infection. The role of CD74 was assessed using histologic analysis, real-time polymerase chain reaction, flow cytometry, and plaque assay. RESULTS: In comparison to wild-type mice, CD74-/- mice developed only mild clinical features and had low levels of tissue damage. Leukocyte infiltration, characterized predominantly by inflammatory monocytes and natural killer cells, was substantially reduced in the infected tissue of CD74-/- mice, but production of proinflammatory cytokines and chemokines was not decreased. CD74 deficiency was associated with increased monocyte apoptosis, but had no effect on monocyte migratory capacity. Consistent with these findings, alphaviral infection resulted in a dose-dependent up-regulation of CD74 expression in human peripheral blood mononuclear cells, and serum MIF levels were significantly elevated in patients with RRV or CHIKV infection. CONCLUSION: CD74 appears to regulate immune responses to alphaviral infection through its effects on cellular recruitment and survival. These findings suggest that both MIF and CD74 play a critical role in mediating alphaviral disease, and blocking these factors with novel therapeutic agents could substantially ameliorate the pathologic manifestations.
OBJECTIVE: Arthrogenic alphaviruses such as Ross River virus (RRV) and chikungunya virus (CHIKV) circulate worldwide. This virus class causes debilitating illnesses that are characterized by arthritis, arthralgia, and myalgia. In previous studies, we identified macrophage migration inhibitory factor (MIF) as a critical inflammatory factor in the pathogenesis of alphaviral diseases. The present study was undertaken to characterize the role of CD74, a cell surface receptor of MIF, in both RRV- and CHIKV-induced alphavirus arthritides. METHODS:Mouse models of RRV and CHIKV infection were used to investigate the immunopathogenesis of arthritic alphavirus infection. The role of CD74 was assessed using histologic analysis, real-time polymerase chain reaction, flow cytometry, and plaque assay. RESULTS: In comparison to wild-type mice, CD74-/- mice developed only mild clinical features and had low levels of tissue damage. Leukocyte infiltration, characterized predominantly by inflammatory monocytes and natural killer cells, was substantially reduced in the infected tissue of CD74-/- mice, but production of proinflammatory cytokines and chemokines was not decreased. CD74 deficiency was associated with increased monocyte apoptosis, but had no effect on monocyte migratory capacity. Consistent with these findings, alphaviral infection resulted in a dose-dependent up-regulation of CD74 expression in human peripheral blood mononuclear cells, and serum MIF levels were significantly elevated in patients with RRV or CHIKV infection. CONCLUSION:CD74 appears to regulate immune responses to alphaviral infection through its effects on cellular recruitment and survival. These findings suggest that both MIF and CD74 play a critical role in mediating alphaviral disease, and blocking these factors with novel therapeutic agents could substantially ameliorate the pathologic manifestations.
Authors: Thomas E Morrison; Alan C Whitmore; Reed S Shabman; Brett A Lidbury; Suresh Mahalingam; Mark T Heise Journal: J Virol Date: 2006-01 Impact factor: 5.103
Authors: Verena Schwartz; Hongqi Lue; Sandra Kraemer; Joanna Korbiel; Regina Krohn; Kim Ohl; Richard Bucala; Christian Weber; Jürgen Bernhagen Journal: FEBS Lett Date: 2009-08-06 Impact factor: 4.124
Authors: Niels C Riedemann; Ren-Feng Guo; Hongwei Gao; Lei Sun; Marco Hoesel; Travis J Hollmann; Rick A Wetsel; Firas S Zetoune; Peter A Ward Journal: J Immunol Date: 2004-07-15 Impact factor: 5.422
Authors: G Fingerle-Rowson; O Petrenko; C N Metz; T G Forsthuber; R Mitchell; R Huss; U Moll; W Müller; R Bucala Journal: Proc Natl Acad Sci U S A Date: 2003-07-23 Impact factor: 11.205
Authors: Inbal Binsky; Michal Haran; Diana Starlets; Yael Gore; Frida Lantner; Nurit Harpaz; Lin Leng; David M Goldenberg; Lev Shvidel; Alain Berrebi; Richard Bucala; Idit Shachar Journal: Proc Natl Acad Sci U S A Date: 2007-08-08 Impact factor: 11.205
Authors: Weiqiang Chen; Suan-Sin Foo; Adam Taylor; Aleksei Lulla; Andres Merits; Linda Hueston; Mark R Forwood; Nicole C Walsh; Natalie A Sims; Lara J Herrero; Suresh Mahalingam Journal: J Virol Date: 2014-10-22 Impact factor: 5.103
Authors: Kothila Tharmarajah; Arun Everest-Dass; Jelena Vider; Xiang Liu; Joseph R Freitas; Helen Mostafavi; Jayaram Bettadapura; Mark von Itzstein; Nicholas P West; Adam Taylor; Suresh Mahalingam; Ali Zaid Journal: J Virol Date: 2022-08-24 Impact factor: 6.549
Authors: Suan-Sin Foo; Weiqiang Chen; Adam Taylor; Kuo-Ching Sheng; Xing Yu; Terk-Shin Teng; Patrick C Reading; Helen Blanchard; Cecilia Garlanda; Alberto Mantovani; Lisa F P Ng; Lara J Herrero; Suresh Mahalingam Journal: PLoS Pathog Date: 2015-02-19 Impact factor: 6.823
Authors: César Trifone; Jimena Salido; María Julia Ruiz; Lin Leng; María Florencia Quiroga; Horacio Salomón; Richard Bucala; Yanina Ghiglione; Gabriela Turk Journal: Front Immunol Date: 2018-06-27 Impact factor: 7.561